NextVivo

About:

NextVivo is a biotech company developing an immune organoid technology platform.

Top Investors: Khosla Ventures, Alexandria Venture Investments, Wilson Sonsini Goodrich & Rosati

Description:

NextVivo is a biotech company developing an immune organoid technology platform to transform the future of drug development. Its mission is to accelerate the development of safer, more effective therapies that are generated and tested in immune-competent human-derived models.

Total Funding Amount:

$7.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Palo Alto, California, United States

Founded Date:

2021-01-01

Founders:

Adam Margolin, Mark Davis

Number of Employees:

1-10

Last Funding Date:

2021-12-09

IPO Status:

Private

Industries: